Spanish Neurology Society consensus document on the use of drugs in multiple sclerosis: Escalating therapy

Article information

Abstract

Introduction

Treatment of multiple sclerosis has advanced considerably in the last few years, at the same time as its complexity has increased. The purpose of this consensus document is to provide specific recommendations and rules on the strategy to follow in the treatment of multiple sclerosis in order to modify its course.

Material and methods

Experts on the treatment and clinical research on multiple sclerosis proposed by the Demyelinating Diseases Group of the Spanish Neurology Society (SEN) prepared an initial document with recommendations for the treatment of this disease. The final version of this document was submitted to members of the Demyelinating Diseases Group of the SEN, who were able to make modifications and suggest changes to the final manuscript.

Results and conclusions

A review has been made of the evidence levels and indications for the treatment of the different clinical forms of multiple sclerosis, and recommendations made for the use of drugs. As well as authorised drugs, a review has also been made of other occasionally used products, as well as combined therapy, therapeutic response criteria, levels of treatment changes, and finally a proposal is made on therapeutic escalation.

Keywords:

Multiple sclerosis

Isolated demyelinating syndrome

Combined treatment

Therapeutic escalation

Resumen

Introducción

La terapéutica de la esclerosis múltiple ha avanzado notablemente en los últimos años al tiempo que ha aumentado su complejidad. El propósito de este documento de consenso es presentar recomendaciones y pautas concretas sobre la estrategia que seguir en el tratamiento para modificar el curso de la esclerosis múltiple.

Material y métodos

Expertos en el tratamiento y en investigación clínica en esclerosis múltiple propuestos por el grupo de enfermedades desmielinizantes de la Sociedad Española de Neurología (SEN) elaboraron un documento inicial con recomendaciones para el tratamiento de esta enfermedad. La versión final de este documento fue remitida a los miembros del grupo de enfermedades desmielinizantes de la SEN, quienes pudieron realizar modificaciones y sugerir cambios al manuscrito final. Tras considerar estas enmiendas, el comité de expertos validó el documento final.

Resultados y conclusiones

Se revisan los niveles de evidencia y las indicaciones para el tratamiento de las diferentes formas clínicas de esclerosis múltiple y se hacen recomendaciones de uso de los medicamentos. Además de los fármacos autorizados, se revisan también otros productos ocasionalmente empleados, así como la terapia combinada, los criterios de respuesta terapéutica, los niveles de cambio de tratamiento y finalmente se hace una propuesta de escalado terapéutico.

Palabras clave:

Esclerosis múltiple

Síndrome desmielinizante aislado

Terapia combinada

Escalado terapéutico

Full text is only aviable in PDF

References

[1.]

The IFNB Multiple Sclerosis Study Group.

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial.

Neurology, 43 (1993), pp. 655-661

Medline

[2.]

K.P. Johnson, B.R. Brooks, J.A. Cohen, C.C. Ford, J. Goldstein, R.P. Lisak, Copolymer 1 Multiple Sclerosis Study Group, et al.

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995.

Neurology, 57 (2001), pp. S16-S24

Medline

[3.]

PRISMS (Prevention of Relapses, Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis.

Lancet, 352 (1998), pp. 1498-1504

Medline

[4.]

Multiple Sclerosis Collaborative Research Group (MSCRG).

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis.

Ann Neurol, 39 (1996), pp. 285-294

http://dx.doi.org/10.1002/ana.410390304 | Medline

[5.]

M.G. Brown, S. Kirby, C. Skedgel, J.D. Fisk, T.J. Murray, V. Bhan, et al.

How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?.

Neurology, 69 (2007), pp. 1498-1507

http://dx.doi.org/10.1212/01.wnl.0000271884.11129.f3 | Medline

[6.]

B.D. Trapp, J. Peterson, R.M. Ransonhof, R. Rudick, S. Mork, L. Bo.

Axonal transection in the lesions of multiple sclerosis.

N Engl J Med, 338 (1998), pp. 278-285

http://dx.doi.org/10.1056/NEJM199801293380502 | Medline

[7.]

Avonex® Medication guide.

[8.]

Betaferon® Medication guide.

[9.]

Extavia® Medication guide.

[10.]

Copaxone® Medical guide.

[11.]

G. Comi, M. Filippi, F. Barkhof, L. Durelli, G. Edan, O. Fernández, Early Treatment of Multiple Sclerosis Study Group, et al.

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

Lancet, 357 (2001), pp. 1576-1582

Medline

[12.]

CHAMPS Study Group.

Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis.

Am J Ophthalmol, 132 (2001), pp. 463-471

Medline

[13.]

L. Kappos, C.H. Polman, M.S. Freedman, G. Edan, H.P. Hartung, D.H. Miller, et al.

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

Neurology, 67 (2006), pp. 1242-1249

http://dx.doi.org/10.1212/01.wnl.0000237641.33768.8d | Medline

[14.]

M. Clerico, F. Faggiano, J. Palace, G. Rice, M. Tintorè, L. Durelli.

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Cochrane Database Syst Rev, 16 (2008),

[15.]

CHMP variation assessment report. London, 27 April 2006. EMEA/CHMP/14147/2006.

[16.]

Rebif® Medication Guide.

[17.]

European Study Group on interferon beta-1b in secondary progressive MS.

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis.

Lancet, 352 (1998), pp. 1491-1497

Medline

[18.]

Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in, MS., (SPECTRIMS) Study Group.

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results.

Neurology, 56 (2001), pp. 1496-1504

Medline

[19.]

H.P. Hartung, R. Gonsett, N. Konig, et al.

Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, doubleblind randomized multicenter trial.

Lancet, 360 (2002), pp. 2018-2025

http://dx.doi.org/10.1016/S0140-6736(02)12023-X | Medline

[20.]

F. Paul, J. Dörr, J. Würfel, H.P. Vogel, F. Zipp.

Early mitoxantroneinduced cardiotoxicity in secondary progressive multiple sclerosis.

J Neurol Neurosurg Psychiatry, 78 (2007), pp. 198-200

http://dx.doi.org/10.1136/jnnp.2006.091033 | Medline

[21.]

C.H. Polman, P.W. O’Connor, E. Havrdova, M. Hutchinson, L. Kappos, D.H. Miller, et al.

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

N Engl J Med, 354 (2006), pp. 899-910

http://dx.doi.org/10.1056/NEJMoa044397 | Medline

[22.]

F. Fazekas, F.D. Lublin, D. Li, M.S. Freedman, H.P. Hartung, P. Rieckmann, PRIVIG Study Group; UBC MS/MRI Research Group Collaborators, et al.

Intravenous immunoglobulin in relapsing remitting multiple sclerosis: a dose-finding trial.

Neurology, 71 (2008), pp. 265-271

http://dx.doi.org/10.1212/01.wnl.0000318281.98220.6f | Medline

[23.]

I. Elovaaraa, S. Apostolskib, P. Van Doornc, N.E. Gilhusd, A. Hietaharjue, J. Honkaniemif, EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases, et al.

EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.

Eur J Neurol, 15 (2008), pp. 893-908

http://dx.doi.org/10.1111/j.1468-1331.2008.02246.x | Medline

[24.]

A. Achiron, I. Kishner, M. Dolev, Y. Stern, M. Dulitzky, E. Schiff, et al.

Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis.

J Neurol, 251 (2004), pp. 1133-1137

http://dx.doi.org/10.1007/s00415-004-0495-z | Medline

[25.]

O. Fernández, V. Fernández, E. De Ramón.

Azathioprine and methotrexate in multiple sclerosis.

J Neurol Sci, 223 (2004), pp. 29-34

http://dx.doi.org/10.1016/j.jns.2004.04.016 | Medline

[26.]

I. Casetta, G. Iuliano, G. Filippini.

Azathioprine for multiple sclerosis.

Cochrane Database Syst Rev, 17 (2007),

[27.]

H.L. Weiner, G.A. Mackin, E.J. Orav, et al.

Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group.

Neurology, 43 (1993), pp. 910-918

Medline

[28.]

R.J. Schwartzman, N. Simpkins, G.M. Alexander, E. Reichenberger, K. Ward, N. Lindenberg, et al.

High-dose cyclophosphamide in the treatment of multiple sclerosis.

CNS Neurosci Ther, 15 (2009), pp. 118-127

http://dx.doi.org/10.1111/j.1755-5949.2008.00072.x | Medline

[29.]

O. Gray, G.V. McDonnell, R.B. Forbes.

Methotrexate for multiple sclerosis.

Cochrane Database Syst Rev, (2004),

[30.]

E. Grapsa, N. Triantafyllou, A. Rombos, A. Lagouranis, M.A. Dimopoulos.

Therapeutic plasma exchange combined with immunomodulating agents in secondary progressive multiple sclerosis patients.

Ther Apher Dial, 12 (2008), pp. 105-108

http://dx.doi.org/10.1111/j.1744-9987.2008.00554.x | Medline

[31.]

R. Gold.

Combination therapies in multiple sclerosis.

J Neurol, 255 (2008), pp. 51-60

http://dx.doi.org/10.1007/s00415-008-1008-2 | Medline

[32.]

F. Costello, O. Stüve, M.S. Weber, S.S. Zamvil, E. Frohman.

Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice.

Curr Opin Neurol, 20 (2007), pp. 281-285

http://dx.doi.org/10.1097/WCO.0b013e328122de1b | Medline

[33.]

O. Fernández.

Combination therapy in multiple sclerosis.

J Neurol Sci, 259 (2007), pp. 95-103

http://dx.doi.org/10.1016/j.jns.2006.08.019 | Medline

[34.]

J. Rio, C. Nos, M. Tintore, et al.

Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.

Ann Neurol, 59 (2006), pp. 344-352

http://dx.doi.org/10.1002/ana.20740 | Medline

[35.]

K. O’Rourke, C. Walsh, G. Antonelli, M. Hutchinson.

Predicting beta-interferon failure in relapsing-remitting multiple sclerosis.

Mult Scler, 13 (2007), pp. 336-342

http://dx.doi.org/10.1177/1352458506071309 | Medline

[36.]

W. Bruck, A. Bitsh, H. Kolenda, Y. Bruck, M. Stiefel, H. Lassmann.

Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology.

Ann Neurol, 42 (1997), pp. 783-793

http://dx.doi.org/10.1002/ana.410420515 | Medline

[37.]

J. Río, C. Nos, M. Tintoré, C. Borras, I. Galan, M. Comabella, et al.

Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials.

Ann Neurol, 52 (2002), pp. 400-406

http://dx.doi.org/10.1002/ana.10290 | Medline

[38.]

L. Durelli, E. Verdun, P. Barbero, et al.

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

Lancet, 359 (2002), pp. 1453-1460

Medline

[39.]

H.P. Hartung.

Early treatment and dose optimisation BENEFIT and BEYOND.

J Neurol, 252 (2005), pp. 44-50

[40.]

D.D. Mikol, F. Barkhof, P. Chang, P.K. Coyle, D.R. Jeffery, S.R. Schwid, REGARD study group, et al.

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

Lancet Neurol, 7 (2008), pp. 903-914

http://dx.doi.org/10.1016/S1474-4422(08)70200-X | Medline

[41.]

C. Caon, M. Din, W. Ching, et al.

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis.

Eur J Neurol, 13 (2006), pp. 471-474

http://dx.doi.org/10.1111/j.1468-1331.2006.01273.x | Medline

[42.]

A. Gajofatto, P. Bacchetti, B. Grimes, A. High, E. Waubant.

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.

Mult Scler, 15 (2009), pp. 50-58

http://dx.doi.org/10.1177/1352458508096687 | Medline

[43.]

P. Rieckmann, K.V. Toyka, Austrian-German-Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG].

Escalating immunotherapy of multiple sclerosis.

Eur Neurol, 42 (1999), pp. 121-127

http://dx.doi.org/8084 | Medline

[44.]

P. Rieckmann, Multiple Sklerose Therapie Konsensus Gruppe (MSTKG).

[Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].

Nervenarzt, 77 (2006), pp. 1506-1518

http://dx.doi.org/10.1007/s00115-006-2220-x | Medline

[45.]

P. Rieckmann, K.V. Toyka, C. Bassetti, K. Beer, S. Beer, U. Buettner, Multiple Sclerosis Therapy Consensus Group, et al.

Escalating immunotherapy of multiple sclerosis-new aspects and practical application.

J Neurol, 251 (2004), pp. 1329-1339

http://dx.doi.org/10.1007/s00415-004-0537-6 | Medline

[46.]

H. Wiendl, K.V. Toyka, P. Rieckmann, R. Gold, H.P. Hartung, R. Hohlfeld, Multiple Sclerosis Therapy Consensus Group (MSTCG).

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

J Neurol, 255 (2008), pp. 1449-1463

http://dx.doi.org/10.1007/s00415-008-0061-1 | Medline

[47.]

J. Ramtahal, A. Jacob, K. Das, M. Boggild.

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

J Neurol, 253 (2006), pp. 1160-1164

http://dx.doi.org/10.1007/s00415-006-0178-z | Medline

[48.]

E. Le Page, G. Edan.

Long-term experience with induction treatment regimens in multiple sclerosis.

J Neurol Sci, 277 (2009), pp. S46-S49

http://dx.doi.org/10.1016/S0022-510X(09)70013-9 | Medline

[49.]

P. Huppke, W. Stark, C. Zürcher, B. Huppke, W. Brück, J. Gärtner.

Natalizumab use in pediatric multiple sclerosis.

Arch Neurol, 65 (2008), pp. 1655-1658

http://dx.doi.org/10.1001/archneur.65.12.1655 | Medline